Inferra AI / Company / LNTH
Lantheus Holdings, Inc.
LNTH · Health Care
Last earnings Aug 6, 2026
Key results
Revenuequarter
$378.0 million
revenue of $378.0 million, GAAP fully diluted
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
EPSquarter
$1.12
earnings per share of $1.12, adjusted fully diluted
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
earnings per share of $1.57 and
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Free cash flowquarter
$79.1 million
free cash flow of $79.1 million •
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Operating incomequarter
14.4%
• Operating income decreased 14.4% to $88.0 million.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Adjusted operating incomequarter
10.8%
Adjusted operating income (non-GAAP) decreased 10.8% to $152.6 million.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Fully EPSquarter
27.3%
• Fully diluted earnings per share increased 27.3% to $1.12, compared to $0.88 in the prior year period.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Adjusted fully diluted earnings per share (non-GAAP) decreased 12.8% to $1.57, compared to $1.80 in the prior year period.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $378.0 million | — | — |
| EPS | $1.12 | — | — |
| Free cash flow | $79.1 million | — | — |
| Operating income | 14.4% | — | — |
| Adjusted operating income | 10.8% | — | — |
| Fully EPS | 27.3% | — | — |
Guidance · company-stated
“$ 378.0 $ 394.1”
“$ 78.8 $ 62.1 26.9 %”
“$ 1.12 $ 0.88 27.3 %”
“(non-GAAP) $ 110.6 $ 126.8”
“of PYLARIFY were $250.6 million”
“decreased 14.4%”
“were $87.1 million and $79.1 million”
Guidance stated in the release's Business Outlook table for full year 2025; no direction stated — figures as stated in the table.
Cash flow & capex
Capital allocation
“Today, we announced the FDA has accepted our NDA for a new PSMA PET formulation and the Board authorized a new $400 million stock repurchase program, which reflects our confidence in our long-term strategy to deliver value for our business, patients, and shareholders.
In November 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20), which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion rather than as extinguishment of debt.
Event summary
Lantheus Holdings, Inc. Q2 2025 — revenue of $378.0 million, GAAP fully diluted
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
revenue: “revenue $ 378.0 $ 394.1”
net income: “net income $ 78.8 $ 62.1 26.9 %”
diluted earnings per share: “diluted earnings per share $ 1.12 $ 0.88 27.3 %”
Adjusted net income: “Adjusted net income (non-GAAP) $ 110.6 $ 126.8”
Sales: “Sales of PYLARIFY were $250.6 million”
Operating income: “Operating income decreased 14.4%”
free cash flow: “free cash flow were $87.1 million and $79.1 million”
revenue (“full year 2025”)
“revenue $ 378.0 $ 394.1”
net income (“full year 2025”)
“net income $ 78.8 $ 62.1 26.9 %”
diluted earnings per share (“full year 2025”)
“diluted earnings per share $ 1.12 $ 0.88 27.3 %”
Adjusted net income (“full year 2025”)
“Adjusted net income (non-GAAP) $ 110.6 $ 126.8”
Sales (“full year 2025”)
“Sales of PYLARIFY were $250.6 million”
Operating income (“full year 2025”)
“Operating income decreased 14.4%”
free cash flow (“full year 2025”)
“free cash flow were $87.1 million and $79.1 million”
Guidance stated in the release's Business Outlook table for full year 2025; no direction stated — figures as stated in the table.
Capital allocation
“Today, we announced the FDA has accepted our NDA for a new PSMA PET formulation and the Board authorized a new $400 million stock repurchase program, which reflects our confidence in our long-term strategy to deliver value for our business, patients, and shareholders.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
In November 2024, the FASB issued ASU 2024-04, Debt - Debt with Conversion and Other Options (Subtopic 470-20), which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion rather than as extinguishment of debt.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The adoption did not have a material impact on the Company s condensed consolidated financial statements during the first quarter of 2026, as the Company has not entered into any exchange-related settlements, modifications, or inducement transactions related to its 2.625 % Convertible Senior Notes due December 2027.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
In connection with that analysis, the Company identified an immaterial embedded derivative that was bifurcated from the host debt contract.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The carrying amount of the host debt instrument was determined after giving effect to the bifurcation of the embedded derivative.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The resulting debt discount on the host debt-instrument is being accreted into other income, net in the Company s condensed consolidated statements of operations over the period the Seller Note remains outstanding.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
“In the second quarter and the month thereafter, we completed the acquisitions of both Evergreen Theragnostics and Life Molecular Imaging – key steps in executing our strategy to expand capabilities across the radiopharmaceutical value chain, diversify revenue, including with Neuraceq, and drive future growth.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
“Today, we announced the FDA has accepted our NDA for a new PSMA PET formulation and the Board authorized a new $400 million stock repurchase program, which reflects our confidence in our long-term strategy to deliver value for our business, patients, and shareholders.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The transaction allows Lantheus to focus on growing its commercial portfolio of innovative PET radiodiagnostics and microbubbles, while advancing its pipeline of radiopharmaceuticals.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Prior to January 1, 2026, the Company classified its revenues into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Following the Company s sale of its SPECT business on January 1, 2026, the Company classifies its revenues into four product categories: Oncology, Neurology, Cardiology, and Strategic Partnerships and Other Revenue.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Such forward-looking statements include our guidance for the fiscal year 2025 and our plans to expand our portfolio of late-stage assets and high potential early-stage candidates, our acquisitions of Evergreen and Life Molecular and our plans to divest our SPECT business to SHINE, and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements.
SEC original ↗Lantheus Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 52 Item 1A.
SEC original ↗Lantheus Holdings, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewLantheus Holdings, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lantheus Holdings, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Lantheus Holdings, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
38 documents- Q3 2026
- 8-KLNTH
Oct 22, 2026
- 8-KLNTH
Oct 14, 2026
- 8-KLNTH
Oct 2, 2026
- Q2 2026
- 8-KLNTH
Sep 21, 2026
- 10-QLNTH
- 8-KLNTH
Aug 6, 2026
- 8-KLNTH
Aug 4, 2026
- 8-KLNTH
Aug 3, 2026
- EX-99LNTH
- Q1 2026
- 10-QLNTH
- 8-KLNTH
May 7, 2026
- 8-KLNTH
May 1, 2026
- Q4 2025
- 10-KLNTH
Feb 26, 2026
- 8-KLNTH
Feb 26, 2026
- Q3 2025
- 8-KLNTH
Nov 12, 2025
- 10-QLNTH
- 8-KLNTH
Nov 6, 2025
- EX-99LNTH
- Q2 2025
- 8-KLNTH
Aug 11, 2025
- 10-QLNTH
- 8-KLNTH
Aug 6, 2025
- EX-99LNTH
- 8-KLNTH
Jul 22, 2025
- EX-99LNTH
Jul 22, 2025
- Q1 2025
- 10-QLNTH
- 8-KLNTH
May 7, 2025
- 8-KLNTH
May 5, 2025
- 8-KLNTH
Apr 1, 2025
- EX-99LNTH
- Q4 2024
- 10-KLNTH
Feb 26, 2025
- 8-KLNTH
Feb 26, 2025
- 8-KLNTH
Jan 30, 2025
- EX-99LNTH
Jan 30, 2025
- 8-KLNTH
Jan 28, 2025
- EX-99LNTH
Jan 28, 2025
- 8-KLNTH
Jan 13, 2025
- EX-99LNTH
Jan 13, 2025
- Q3 2024
- 8-KLNTH
Dec 23, 2024
Earnings releases
7 documentsPresentations
3 documents
Transcripts
0 documentsNo transcripts for Lantheus Holdings, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.